246.37
+2.95%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Piramal Pharma
Its shares trade on NSE under the ticker PPLPHARMA.NS. It has been listed since 19 October 2022. In the fiscal year to 31 March 2026, it reported revenue of ₹88.69bn and a net loss of ₹3.26bn. At that date it held total assets of ₹179.65bn and shareholders' equity of ₹81.63bn.
Piramal Pharma Ltd. engages in development and manufacturing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2022-10-19. The firm has approximately 17 global facilities and a global distribution network in over 100 countries. The firm's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain, anesthetics, injectable anti-infectives, and other therapies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Oct 2022
- Employees
- 6,295
Leadership
Pay as last reported
- Ms. Nandini PiramalExecutive Chairman of the Board, since 2020₹42.0m
- Mr. Vivek ValsarajChief Financial Officer, Executive Director, since 2022₹24.8m
- Ms. Tanya SanishCompliance Officer, Company Secretary
- Mr. Peter DeyoungExecutive Director, Chief Executive Officer of Global Pharma, since 2020₹42.4m
- Mr. Amit JainAdditional Non-Executive Non-Independent Director
- Ms. Nathalie LeitchNon-Executive Non- Independent Director₹3.9m
- Mr. Sridhar GorthiNon-Executive Independent Director₹4.2m
- Mr. Jairaj PurandareNon-Executive Independent Director₹4.5m
- Mr. S. RamadoraiNon-Executive Independent Director₹4.3m
- Ms. Vibha RishiNon-Executive Independent Director₹4.3m
- Mr. Peter StevensonNon-Executive Independent Director₹3.8m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Piramal Pharma Solutions provides end-to-end development and manufacturing solutions globally.
- Piramal Critical Care offers complex hospital generics including inhalation anesthetics and injectable therapies.
- Piramal Pharma has a global distribution network spanning over 100 countries with 17 facilities.
Weaknesses
- Piramal Pharma Solutions operates in a highly competitive pharmaceutical market.
- Piramal Critical Care faces challenges in the complex hospital generics segment.
- Piramal Pharma's IPO was in 2022, limiting its market history.
Opportunities
- Piramal Pharma can expand its global distribution network into new markets.
- Piramal Critical Care can grow its portfolio of complex hospital therapies.
- Piramal Pharma Solutions can leverage its integrated network for new product development.
Threats
- Piramal Pharma Solutions faces regulatory challenges in global markets.
- Piramal Critical Care must navigate pricing pressures in hospital generics.
- Piramal Pharma's global facilities may encounter supply chain disruptions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.